We serve Chemical Name:9-Ethynyl-9H-fluoren-9-ol CAS:13461-74-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:9-Ethynyl-9H-fluoren-9-ol
CAS.NO:13461-74-0
Synonyms:9H-Fluoren-9-ol, 9-ethynyl-;9-ethynylfluoren-9-ol;9-Ethynyl-9H-fluoren-9-ol;L B656 HHJ HQ H1UU1;9-Ethynyl-9-hydroxyfluorene;9-Ethynyl-9-fluorenol;(9-Hydroxy-9-fluorenyl)acetylene;MFCD00041555
Molecular Formula:C15H10O
Molecular Weight:206.239
HS Code:2906299090
Physical and Chemical Properties:
Melting point:107-110 °C
Boiling point:375.2±31.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.696
PSA:20.23000
Exact Mass:206.073166
LogP:3.13
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 9H-Fluoren-9-ol, 9-ethynyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00041555 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-Ethynyl-9-hydroxyfluorene Use and application,9-Ethynyl-9-fluorenol technical grade,usp/ep/jp grade.
Related News: Delta said it will suspend flights between the United States and China starting on Sunday until at least April 30, according to a press release. 9-Ethynyl-9H-fluoren-9-ol manufacturer Delta said it will suspend flights between the United States and China starting on Sunday until at least April 30, according to a press release. 9-Ethynyl-9H-fluoren-9-ol supplier For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” 9-Ethynyl-9H-fluoren-9-ol vendor Delta said it will suspend flights between the United States and China starting on Sunday until at least April 30, according to a press release. 9-Ethynyl-9H-fluoren-9-ol factory For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.”
